Am I a good candidate for an implanted venous access device?

 

Q: Am I a good candidate for an implanted venous access device? 

A: A venous access device, or VAD, is a catheter or port that is surgically placed in your body to give access to a major vein. These devices are often used with patients who are receiving long-term chemotherapy, chemotherapy that is infused by a portable pump over days, frequent blood tests, transfusions, or other treatment-related care. Some patients on chemotherapy receive VAD implants, others don't.

Whether you will have a VAD depends upon your treatment plan, the physical condition of your veins, and other factors your doctor will consider. While you're in treatment, your VAD will need to be flushed after each session to keep it from becoming clogged. After treatment ends, you'll need to have it flushed every 4 to 6 weeks.
--Bernice Crook, RN, OCN

Cancer patients have greater risk of blood clots, but can watch for danger signals.

Latest Cancer News
Multiple-agent Therapy with Metronomic Xeloda® and Nexavar® Promising for Metastatic Renal Cell Carcinoma

March 12, 2010 — Researchers from Spain have reported: “Maximum tolerated dose chemotherapy followed by metronomic chemotherapy” is a promising approach for treatment of patients with metastatic renal cell carcinoma (RCC). The details of this study were published early online in Lancet Oncology on February 16, 2010.

Complete Remission Predicts for Long Survival of Patients with Multiple Myeloma

March 12, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that achieving a complete remission (CR) was the dominant prognostic factor for long survival of patients with multiple myeloma (MM). The details of this large retrospective review were published in the March 2010 issue of Bone Marrow Transplantation.

Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer

March 12, 2010 — Researchers affiliated with the RTOG 94-08 clinical trial have reported that short-term androgen deprivation therapy (ADT) delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco on March 5-7.

Select news items provided by Reuters Health